Prenetics Global Limited
NASDAQ:PRE · NASDAQ Global Market
+$0.43 today
Vol 0.14M · Avg 0.22M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-21.6%
avg -34.5%
ROIC
-21.5%
avg -38.1%
ROA
-18.5%
avg -44.8%
Analysis
ROA is currently the strongest return metric at -18.5% versus its period average of -44.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Chi Hung Tzang | Co-Founder & Chief Scientific Officer | — | — | 51 | — | — |
Samantha Kwok | Chief of Staff to Group Chief Executive Officer & Vice President of People & Operations | — | — | — | — | — |
Senthil Sundaram | Chief Clinical Officer | — | — | 52 | — | — |
James DiNicolantonio | Chief Nutrition Officer, Member of Scientific & Medical Advisory Board | — | — | — | — | — |
Brian J. Rosin | Chief Financial Officer | — | — | — | — | — |
Hoi Chun Lo | Chief Financial Officer | — | — | 40 | $597,930.00 | 3.52% |
David Eric Vanderveen | President of Americas | — | — | 57 | $0.00 | <0.01% |
Joel Neoh | Chief Consumer Officer | — | — | 42 | — | — |
Sheng Wu Yeung | Co-Founder, Chairperson & Chief Executive Officer | — | — | 47 | $647,592.00 | 3.81% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -30.6% | +83.8% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -30.6% over three years. Forward estimates point to Revenue at +83.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
OraSure Technologies, Inc.
NASDAQ:OSUR
$297.08M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$258.63M
Codexis, Inc.
NASDAQ:CDXS
$224.97M
Profound Medical Corp.
NASDAQ:PROF
$206.07M
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
$148.80M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$143.33M
MaxCyte, Inc.
NASDAQ:MXCT
$126.40M
Neuronetics, Inc.
NASDAQ:STIM
$84.55M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$72.50M
Atlantic International Corp.
NASDAQ:ATLN
$41.58M
Who manages PRE?
Prenetics Global Limited (PRE) lists 9 active executives. The top listed executive is Chi Hung Tzang, Co-Founder & Chief Scientific Officer.
Are PRE insiders buying or selling?
Recent insider activity shows net selling of $83.12M.
Explore More
Continue the stock analysis
Jump to another research area for this company.